Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Clinical trial NCT02821013 · RECRUITING

Trial details

NCT number: NCT02821013
Sponsor: Canadian Cancer Trials Group
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Unresectable/Metastatic Melanoma

Start date: 2016-10-31
Primary completion: 2027-12-31
Enrollment: 614

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.